May 3, 2016 News by Margarida Azevedo, MSc Opexa’s CEO Gives Update on T-Cell Therapy at Vatican Conference Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact held at the Vatican. Neil…
November 25, 2015 News by Patricia Silva, PhD Opexa Therapeutics’ MS Therapy Selected as ‘Top Project to Watch’ Opexa Therapeutics announced that it has been named one of the “Top Projects to Watch” for the third consecutive year. A panel of independent experts recognized the biopharmaceutical company for its work in the development of personalized immunotherapies for autoimmune disorders, such as multiple sclerosis (MS) and neuromyelitis optica (NMO). Opexa was…
August 28, 2015 News by Patricia Silva, PhD Cryoport, Inc. to Supply Opexa’s MS and NMO Immunotherapy Studies with Cryogenic Logistics Solutions Cryoport, Inc., a leader in providing advanced cryogenic logistics solutions for the life sciences industry, has just announced it will be supplying Opexa Therapeutics’ lead personalized T-cell immunotherapy research initiatives for Multiple Sclerosis (MS) and Neuromyelitis Optica (“NMO”). Opexa’s breakthrough immunotherapy drug platform has shown the potential to improve the lives of…
June 2, 2015 News by Maureen Newman SPMS Therapy Developer Opexa Looks to Treat Patients With Neuromyelitis Optica Neuromyelitis optica (NMO), a rare autoimmune disorder often mistaken for multiple sclerosis, is similar in that it is characterized by myelin destruction in the optic nerves and spinal cord. In contrast to multiple sclerosis, as reported by the Transverse Myelitis Association, NMO does not initially affect…
May 4, 2015 News by Maureen Newman EXCLUSIVE: Opexa Developing Tcelna as a True Personalized MS Therapy For SPMS, RRMS After the Phase 2b clinical trial named Abili-T achieved full enrollment with 190 secondary progress multiple sclerosis (SPMS) patients, The Woodlands, Texas-based Opexa Therapeutics is patiently awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016.
March 11, 2015 News by Charles Moore SPMS Drug Developer Opexa Therapeutics To Receive $3M Payment from Merck Serono Under Amended Agreement Opexa Therapeutics, Inc. a biopharmaceutical company headquartered in Woodlands, Texas, has announced the successful conclusion of negotiations amending its option and license agreement with Darmstadt, Germany based pharma multinational Merck’s “Merck Serono” division. Under terms of the revised agreement, Opexa will receive a $3 million payment to…
October 24, 2014 News by Patricia Silva, PhD Opexa Joins National Multiple Sclerosis Society to Sponsor Walk MS The National Multiple Sclerosis Society‘s Lone Star Chapter, which is sponsoring the nonprofit organization’s annual Houston-area Walk MS fundraisers, has announced that Woodlands-based biopharmaceutical company Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort. This is the fourth consecutive…
May 16, 2014 by Patricia Silva, PhD New Secondary Progressive MS Drug Trial Completes Enrollment Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing Tcelna®, a breakthrough T-cell immunotherapy for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to test Tcelna as a viable…
